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Introduction
Surveillance of resistance to drugs against tuberculosis (TB) is 
a cornerstone of any TB control programme. Surveillance data 
on drug resistance are needed to track the effectiveness of TB 
prevention and control activities; accurately forecast the need 
for patient treatments and plan accordingly; design standard-
ized regimens for the treatment of drug-resistant TB; assess 
epidemiological trends; and promptly identify and respond to 
outbreaks of drug-resistant TB.1 Since 1994 the Global Project 
on Anti-Tuberculosis Drug Resistance Surveillance of the 
World Health Organization (WHO) has supported national 
TB control programmes worldwide in implementing drug 
resistance surveillance activities. Country data are routinely 
collected, analysed and disseminated to describe the global 
problem of drug-resistant TB.2–11
Patients whose mycobacteria are resistant to rifampicin, 
isoniazid and other anti-TB drugs require longer, expensive 
and more toxic treatment regimens and are less likely to be 
cured. This presents a formidable challenge to programmes, 
particularly in low-resource settings.12 Policy guidance on the 
programmatic management of drug-resistant TB13–15 and on 
how to control the transmission of resistant strains16 has been 
developed by WHO, and access to quality-assured second-line 
anti-TB drugs for the treatment of multidrug-resistant TB 
(MDR-TB) is facilitated through the Green Light Commit-
tee mechanism.17 The number of TB patients diagnosed and 
treated for MDR-TB, which is defined as TB caused by strains 
of Mycobacterium tuberculosis that are resistant to at least 
isoniazid and rifampicin,13 is increasing worldwide, but much 
remains to be done. In 2010, only 16% of the TB patients esti-
mated to have MDR-TB were diagnosed and given appropriate 
treatment.11,12, Routine surveillance of drug resistance must be 
linked to patient care.
Over the past three years, WHO has been actively encour-
aging countries to establish continuous TB drug resistance 
surveillance systems based on routine drug susceptibility 
testing of all patients, with priority given to patients previ-
ously treated, who are at highest risk of developing drug 
resistance.18–20 Although limited laboratory capacity for drug 
susceptibility testing still represents a major obstacle to the 
establishment of surveillance systems in low-resource settings, 
new diagnostic tools such as line probe assays21 and Xpert 
MTB/RIF,22 combined with greater resources for laboratory 
strengthening, offer an unprecedented opportunity to scale 
up surveillance systems worldwide.
In this paper we evaluate the existing information on 
anti-TB drug resistance surveillance, with an emphasis on 
data reported in 2007–2010, after the publication of WHO’s 
fourth global report on anti-TB drug resistance surveillance.8,9 
We present a global overview of the extent of the problem of 
MDR-TB, explore associations between MDR-TB and human 
immunodeficiency virus (HIV) infection and sex, discuss 
time trends in drug resistance, and present available data on 
extensively drug-resistant TB (XDR-TB) – the latter defined 
as MDR-TB plus resistance to a fluoroquinolone and at least 
one second-line injectable agent (amikacin, kanamycin or 
capreomycin).13
Methods
Definitions and data collection
Drug resistance surveillance data are gathered following three 
main principles: (i) the data are representative of TB cases 
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in the country or geographical setting 
under study; (ii) drug resistance among 
new TB cases is examined separately 
from drug resistance among previously 
treated TB cases; and (iii) laboratory 
methods for drug susceptibility testing 
are selected from among those that are 
recommended by WHO, with quality 
assurance for all laboratory processes 
conducted in cooperation with a part-
ner supranational reference laboratory 
from the global network of 29 such 
laboratories.18,19,23,24
Drug resistance surveillance data 
are collected separately for new (pre-
viously untreated) and previously 
treated TB cases25 via special surveys 
or continuous surveillance. Special 
surveys measure drug resistance among 
a representative sample of notified 
cases of smear-positive pulmonary 
TB; continuous surveillance systems 
are based on routine diagnostic drug 
susceptibility testing in all bacteriologi-
cally-confirmed TB patients. Aggregated 
data from special surveys are collected 
through a standard data collection form, 
whereas continuous surveillance data 
are captured through “WHO[’s ] global 
TB data collection system”.26 WHO 
ascertains whether survey and continu-
ous surveillance data meet quality and 
representativeness standards through 
criteria detailed elsewhere.10 The main 
indicator reported to estimate the fre-
quency of MDR-TB is the proportion 
of confirmed TB cases with resistance 
to rifampicin and isoniazid. Data on 
resistance to any fluoroquinolone and 
second-line injectable agent among 
confirmed cases of MDR-TB are used 
to estimate the frequency of XDR-TB.
Data description, analysis and 
trends
The proportions of new and previously 
treated TB cases with MDR-TB and 
the proportion of MDR-TB cases with 
XDR-TB were calculated using the latest 
available national and subnational data. 
To derive global estimates for these indi-
cators and to investigate the association 
between MDR-TB and HIV infection 
and sex, individual-level analyses were 
conducted using random-effects or ro-
bust standard errors logistic regression 
models to account for the clustering 
effect at the level of a country or ter-
ritory. We used the I2 index27 to assess 
heterogeneity in country-level odds 
ratios (OR) before we combined these 
to obtain a pooled estimate. STATA ver-
sion 11 (StataCorp. LP, College Station, 
United States of America) was used for 
all analyses.
Time trends in MDR-TB rates (an-
nual number of new cases per 100 000 
population)28 between 1994 and 2010 
were calculated by multiplying the new 
TB case notification rates reported 
annually to WHO11 by the reported 
frequency of MDR-TB among new 
TB cases in the same setting and year. 
Exponential lines were fitted and the 
annual percentage change in the rate 
of MDR-TB was calculated for settings 
where anti-TB drug resistance had been 
measured in at least three different years.
Results
Since the launch of the Global Project 
on Anti-tuberculosis Drug Resistance 
Surveillance in 1994, drug resistance 
data have been systematically collected 
and analysed from 127 countries, or 66% 
of WHO’s 193 Member States. This in-
cludes 64 countries that have continuous 
surveillance systems based on routine 
diagnostic drug susceptibility testing of 
all patients. The remaining 63 countries 
have relied on special surveys of repre-
sentative samples of patients. Of the 127 
countries with surveillance information, 
56 have data from one year only, 20 from 
two years, and 51 from three or more 
years (Fig. 1).
Most recent data, 2007–2010
Between 2007 and 2010, resistance to 
first-line anti-TB drugs was reported 
from 80 countries and 8 territories, 72 
of which provided data from continuous 
surveillance and 16 from special surveys 
(Table 1, available at: http://www.who.
int/bulletin/volumes/90/2/11-092585). 
Almost all countries (82/88, or 93%) 
reported nationwide data. Bangladesh 
(14 districts covering a population of 
30 million), the Plurinational State of 
Bolivia, Chile, Colombia, El Salvador, 
Fiji, Kazakhstan, Lebanon, Mongolia, 
the Republic of Moldova, Rwanda and 
Sri Lanka provided continuous surveil-
lance data on previously treated but not 
new TB cases. Subnational data were 
reported from Bangladesh, the Central 
African Republic, Indonesia, the Rus-
sian Federation (12 oblasts [administra-
tive regions] and republics), Tajikistan 
and Uganda.
The proportion of new TB cases 
reported as showing multidrug resis-
tance in these years ranged from 0% 
to 28.9%. Proportions exceeding 12% 
(in countries reporting more than 10 
MDR-TB cases) were documented in 
Belarus (25.7%), Estonia (18.3%), sev-
eral oblasts of the Russian Federation 
(with Murmansk having the highest 
level, 28.9%) and Tajikistan (Dushanbe 
city and Rudaki district, 16.5%).
The proportion of previously treat-
ed cases having MDR-TB ranged from 
0% to 65.1%. Countries or subnational 
areas with proportions exceeding 50% 
included Belarus (60.2%), Lithuania 
(51.5%), the Republic of Moldova 
(65.1%), five oblasts of the Russian Fed-
eration, and Tajikistan (Dushanbe city 
and Rudaki district, 61.6%) (Table 1).
The largest country that conducted 
a nationwide survey in the reporting 
period was China, where 5.7% of new 
TB cases and 25.6% of previously treated 
cases were found to have multidrug 
resistance (Table 1).
Surveillance data on XDR-TB were 
reported from 38 countries and 3 ter-
ritories, 34 of which routinely test all 
patients with MDR-TB for second-line 
anti-TB drug resistance. Only 6 out of 41 
(15%) countries and territories reported 
more than 10 cases of XDR-TB; the pro-
portion of MDR-TB cases that were ex-
tensively drug-resistant exceeded 10% in 
Estonia (19.7%), Latvia (15.1%), South 
Africa (10.5%) and Tajikistan (Du-
shanbe city and Rudaki district, 21.0%) 
(Table 2, available at: http://www.who.
int/bulletin/volumes/90/2/11-092585).
Overall data, 1994–2010
The proportions of new and previously 
treated TB cases in the world that were 
multidrug resistant are shown in Fig. 2 
and Fig. 3, respectively. Overall, when 
data from all countries and territories 
were combined, the global proportions 
of new and previously treated TB cases 
showing multidrug resistance were 3.4% 
(95% CI: 1.9–5.0) and 19.8% (95% CI: 
14.4–25.1), respectively. Regional level 
estimates of the proportion of cases with 
MDR-TB are shown in Table 3.
XDR-TB has been identified in 77 
countries globally, and 57 countries 
and 3 territories were able to report 
representative data from continuous 
surveillance or special surveys on the 
proportion of XDR-TB cases among 
MDR-TB cases. Combined data from 
all countries and territories showed that 
the proportion of MDR-TB cases with 
extensive drug resistance was 9.4% (95% 
CI: 7.4–11.6).
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Fig. 2. Distribution of percentage of new tuberculosis cases with multidrug-resistant tuberculosis (MDR-TB)
Note: Showing latest available data, 1994–2010. Reported data for the Democratic Republic of the Congo, Luxembourg, New Caledonia and the Solomon Islands 
are not disaggregated by new and previously treated tuberculosis cases and are therefore not shown.
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Risk factors
When data from 17 countries and 1 ter-
ritory that reported drug resistance data 
stratified by HIV status were combined, 
the odds of having MDR-TB among 
HIV-positive cases were found to be 
40% higher than among HIV-negative 
cases (pooled odds ratio, OR: 1.4; 95% 
CI: 0.7–3.0; OR consistent across coun-
tries, I2 = 23.2%; P-value = 0.19), but the 
difference was not significant. Thus, no 
association was noted between the pres-
ence of MDR-TB and HIV status.
A total of 58 countries and 2 spe-
cial territories reported drug resistance 
surveillance data disaggregated by sex. 
Overall, when data from these settings 
were combined, the odds of having 
MDR-TB were found to be 10% higher 
among females than males (OR: 1.1; 95% 
CI: 0.8–1.4; OR heterogeneous across 
countries, I2 = 32.9%; P-value = 0.009), 
but the difference was not significant. 
Thus, no association was noted between 
the presence of MDR-TB and the sex of 
the patient.
Time trends
Data on time trends in drug resistance 
were available from 71 countries and 
751 country-year data points. Selected 
data to illustrate the diversity of trends 
in TB and MDR-TB worldwide are 
presented in Fig. 4. In a first group 
of countries, composed of Botswana, 
Peru and the Republic of Korea, the 
estimated notification rate of MDR-
TB is increasing (+10.9%, +19.4% 
and +4.3% per year, respectively). In 
these countries, trends in notifica-
tions of new TB cases vary, with a 
clear increase in the Republic of Ko-
rea (+7.4% per year), a rather stable 
trend in Botswana (+0.3% per year) 
and a clear decline in Peru (−3.3% per 
year). A second group is composed of 
three Russian oblasts where TB noti-
fication rates are stable or decreasing. 
Although in these oblasts MDR-TB 
rates were on the rise until around 
2005–2006, they have subsequently 
been falling in all three settings. In a 
third group of countries, composed of 
Estonia, Latvia and the United States, 
surveillance data suggest that both TB 
and MDR-TB rates have been falling 
for more than a decade. In the United 
States the rate of MDR-TB is falling 
even more quickly than the TB case 
notification rate.
Fig. 3. Percentage of previously treated tuberculosis patients with multidrug-resistant tuberculosis (MDR-TB)
Note: Showing latest available data, 1994–2010. Reported data for the Democratic Republic of the Congo, Luxembourg, New Caledonia and the Solomon Islands 
are not disaggregated by new and previously treated tuberculosis cases and are therefore not shown.
Table 3. Average proportions of cases of tuberculosis, new or previously treated, that 
are multidrug-resistant in regions of the World Health Organization (WHO) and 
the world, 1994–2000
WHO region New cases Previously treated cases
% 95% CI % 95% CI
African region 1.9 0.6–3.3 9.4 3.0–15.8
Region of the Americas 2.1 0.7–3.4 11.5 3.8–19.2
Eastern Mediterranean region 3.4 0.9–5.9 20.6 7.5–33.7
European regiona 12.1 8.6–15.6 36.5 32.5–40.6
South-East Asia region 2.1 1.7–2.5 17.2 16.5–17.7
Western Pacific region 4.9 3.6–6.1 23.2 19.6–26.9
World 3.4 1.9–5.0 19.8 14.4–25.1
CI, confidence interval.
a The values for Europe reflect the high levels of multidrug resistance documented in eastern European 
countries: 14.3% (95% CI: 12–16.7) among new cases and 39% (95% CI: 35.1–42.9) among previously 
treated cases of tuberculosis.
Note: The data were obtained from the World Health Organization.10,11
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Discussion
In 2007–2010, several countries pro-
vided drug resistance surveillance data 
generated from continuous surveillance 
systems rather than special surveys, 
a change from previous reports.8,9 Of 
particular interest is a group of 12 coun-
tries that have succeeded in establishing 
continuous surveillance systems for 
previously treated TB cases: Bangladesh 
(14 districts covering a population of 
30 million), the Plurinational State of 
Bolivia, Chile, Colombia, El Salvador, 
Fiji, Kazakhstan, Lebanon, Mongolia, 
the Republic of Moldova, Rwanda and 
Sri Lanka. This is the first step towards 
routine drug susceptibility testing for all 
TB cases and allows early identification 
of drug resistance in the population at 
greatest risk.18–20
Available data confirm that eastern 
Europe and central Asia continue to 
have the world’s highest proportion of 
MDR-TB among TB cases. In 2007–2010 
the highest proportions ever reported 
globally were documented in areas of 
the former Soviet Union; MDR-TB was 
reported among nearly 30% of new TB 
cases in the oblast of Murmansk in the 
Russian Federation and among 65% 
of previously treated TB cases in the 
Republic of Moldova. In a few other 
oblasts of the Russian Federation in the 
same region, levels of MDR-TB appear 
to be stabilizing or even decreasing, 
which confirms that addressing MDR-
TB is feasible even in high-burden areas. 
Unfortunately, large parts of eastern 
Europe and central Asia still lack repre-
sentative data. This applies to the whole 
of Kyrgyzstan and most of Azerbaijan, 
the Russian Federation, Tajikistan, 
Turkmenistan, Ukraine and Uzbekistan. 
With planned and ongoing surveys and 
improvements in continuous surveil-
lance in these countries, major strides 
towards improving our understanding 
of the true burden of drug-resistant TB 
are expected in the near future.
China conducted its first nation-
wide survey in 2007. The survey, which 
confirmed previously published esti-
mates8,9 based on extrapolation from 
subnational level data, represents a 
critical step towards addressing MDR-
TB in one of the largest TB control pro-
grammes in the world. Whereas China 
has been able to conduct a nationwide 
survey, India and the Russian Federation 
– the other two large countries that, with 
China, contribute to more than 50% of 
the estimated global burden of MDR-TB 
Fig. 4. Time trends in population rates of new cases of tuberculosis (TB) and new cases of multidrug-resistant tuberculosis (MDR-TB)
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Note: Data are for new TB cases, except for those of the United States of America, whose data are for combined new and previously treated TB cases.
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– have only produced reliable subna-
tional level data to date. To understand 
the magnitude of the MDR-TB problem 
and address it, nationwide surveillance 
systems should be established in all 
countries, with greater urgency in the 
highest burden settings.
Only 34 countries and settings 
have a system in place to routinely test 
all patients with MDR-TB for second-
line anti-TB drug resistance. These are 
generally countries with established 
or emerging economies, as laboratory 
capacity for second-line drug suscepti-
bility testing in resource-limited settings 
is still scarce.
The average proportions of MDR-
TB cases among diagnosed TB cases 
detected in this study are consistent 
with previous reports.8,9 The lack of data 
on drug-resistant TB in most African 
countries is still a matter of major con-
cern (Fig. 2 and Fig. 3). This situation 
should be urgently addressed, especially 
since the African Region accounts for 
over 80% of the TB cases among people 
living with HIV and since higher 
mortality from MDR-TB and XDR-TB 
has been documented in HIV-positive 
patients.29 The availability of new mo-
lecular technologies for diagnosing TB 
and detecting rifampicin resistance, 
including line probe assays and Xpert 
MTB/RIF, represent an unprecedented 
opportunity for countries with severely 
limited laboratory infrastructure to di-
agnose drug resistance more easily. Line 
probe assays permit safer transportation 
of specimens, require a lower workload 
than conventional culture and drug 
susceptibility tests, and reduce to two 
days the time needed for the diagnosis 
of MDR-TB.30,31 Xpert MTB/RIF is an 
automated nucleic acid amplification 
technology that detects rifampicin 
resistance in less than two hours. It is 
very simple to use and requires limited 
training and biosafety measures.22 A few 
countries have piloted the use of mo-
lecular technologies in drug resistance 
surveys,30,31 but data from surveys using 
exclusively those techniques are not yet 
available. Molecular technologies are 
expected to contribute substantially to 
surveillance of drug-resistant TB in low-
resource settings in the future.
The ana lys is  of  r i sk  fac tors  for 
MDR-TB showed that the overall risk 
of harbouring MDR-TB strains is not 
influenced by sex. The sex distribution 
of patients with MDR-TB does not differ 
from that of patients with drug-suscep-
tible TB. This finding is not surprising, 
since MDR-TB is a form of TB and has 
similar risk factors. Countries where an 
association is documented should be 
investigating the possible reasons.
Although an association between 
HIV infection and MDR-TB has been 
widely documented in hospital out-
breaks of drug-resistant TB among 
people living with HIV,32–34 the pop-
ulation-based data gathered to date 
suggest that the relationship between 
multidrug resistance and HIV infec-
tion is not consistent across settings 
(although the available data are limited 
to a few countries). In addition, HIV 
status is unknown for large proportions 
of patients in these cohorts. Countries 
are still experiencing great difficulties in 
incorporating HIV testing in drug re-
sistance surveys, as this requires strong 
collaboration between HIV and TB 
control programmes. Understanding the 
relationship between HIV infection and 
drug-resistant TB at the population level 
is critical to identify high-risk groups in 
need of additional support.
Trend analysis suggests that MDR-
TB can be controlled once bold policy 
decisions are put into practice and the 
correct prevention and control measures 
are implemented. This is illustrated by 
recent findings reported from selected 
oblasts in the Russian Federation, where 
MDR-TB has been recognized as a 
serious problem since the time of the 
dissolution of the Soviet Union. In 
Arkhangelsk, Tomsk and Orel oblasts, 
TB case notifications are stable or de-
creasing, and although MDR-TB rates 
were increasing until 2005–2006, more 
recent data show a stabilizing (Arkhan-
gelsk) or even declining trend (Tomsk 
and Orel). These settings, which have 
been treating many cases with MDR-
TB in recent years, show that MDR-TB 
can be controlled even in places heavily 
affected by drug resistance. The same 
can be said for Estonia and Latvia, where 
TB and MDR-TB have been declining 
for more than a decade. In the United 
States, rates of MDR-TB are falling even 
more quickly than rates of TB. These 
last three countries have strong control 
programmes that have succeeded in 
reducing both susceptible and resistant 
forms of TB. In contrast, in the Republic 
of Korea, TB and MDR-TB notifications 
are both increasing, the latter more 
rapidly than the former. The diversity of 
treatment options and case management 
in the country, particularly in the large 
private health sector, may be facilitating 
the development of drug resistance.35 
In Botswana TB notification rates have 
stabilized, whereas in Peru they have 
declined, in line with previous assess-
ments.36 However, in both countries 
MDR-TB notification rates are showing 
a very marked increase.
Conclusion
Following 15 years of intensive effort, 
high-quality surveillance data on anti-
TB drug resistance are available for two 
thirds of all countries in the world. These 
data show where MDR-TB rates are 
highest and demonstrate that in selected 
settings a proper response can alleviate 
the problem. At the same time, global 
trends in rates of MDR-TB remain 
unclear, largely because national repre-
sentative data are lacking in many large 
countries, including India and several 
African countries. A better understand-
ing of epidemiological trends in drug re-
sistance at the global and national levels 
can be achieved only through repeated 
surveys and, ultimately, by establish-
ing continuous surveillance based on 
routine drug susceptibility testing of all 
confirmed TB cases, with priority given 
to previously treated patients. Special 
studies are also needed to help us better 
understand the factors conducive to the 
development and spread of MDR-TB. If 
properly and intensively implemented 
and followed by appropriate treatment 
of all TB patients, new technologies can 
accelerate the response to the threat of 
drug resistance, save lives and reduce 
the burden TB imposes on individuals, 
households and communities. ■
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صخلم
2010-2007 ،ثّدحم ليلحت :لماعلا في لسلل ةداضلما ةيودلأا ةمواقم ةبقارم
 فاشكتساو  ةيودلأل  مواقلما  لسلل  يلماع  ثيدتح  ميدقت  ضرغلا
.2010و 1994 ينب مايف تاهاتجلاا
 لسلا ضىرم ينب ةيودلأا ةمواقمب ةصالخا تانايبلا ليلتح مت ةقيرطلا
 نادلبلا  نم  ةعوفرلما  ريراقتلا  قفو  مهجلاع  قبس  نيذلاو  ددلجا
 للاخ  نم  تانايبلا  هذه  عيمتج  متو  .ةيلماعلا  ةحصلا  ةمظنم  لىإ
 ينيتورلا  رابتخلاا لىع ًءانب  ةبقارلما  مظن وأ ضىرملل ةيليثتم حوسم
 مواقلما لسلا ينب تاطابترلاا فاشكتسا متو .ةيئاودلا ةيساسحلل
 ةعانلما  صقن  سويرف  ىودعو  )MDR-TB(  ةددعتلما  ةيودلأل
 .يتسجوللا دادترلاا للاخ نم سنلجاو )HIV( ةيشربلا
 ميلاقأ 8و اًدلب 80 تغلبأ ،2010و 2007 يماع ينب مايف جئاتنلا
 ةددعتلما ةيودلأل مواقلما لسلا تلادعم تناكو .ةبقارلما تانايب نع
 سيورلا داتحلاا في لىعأ اهجلاع قبس يتلاو ،ةديدلجا تلاالحا ينب
 ،)%65.1( افودلوم ةيروهجمو )%28.9 ،تسلابوأ كسنامروم(
 مواقلما لسلا تلااح نم %10  نم رثكأ ةبسن تناكو .لياوتلا لىع
 داتحلاا نادلب نم ةثلاث في ةيودلأل ةمواقلما ةديدش ةددعتلما ةيودلأل
 تظحول ،يلماعلا ديعصلا لىعو .ايقيرفأ بونجو قباسلا يتيفوسلا
 في 2010و 1994 يماع ينب ام ةترفلا في ةددعتلما ةيودلأل ةمواقم
 عيجم  نم  )5.0-1.9  :ةقثلا  لماعم  ،%95  ةقثلا  لماعم(  %3.4
 لماعم  ،%95  ةقثلا  لماعم(  %19.8  فيو  ةديدلجا  لسلا  تلااح
 لمو  .اهجلاع  قبس  يتلا  لسلا  تلااح  نم  )25.1-14.4  :ةقثلا
 ةددعتلما  ةيودلأل مواقلما  لسلا  ينب ةماع تاطابترا  لىع روثعلا  متي
 )HIV(  ةيشربلا  ةعانلما  صقن  سويرف  ىودعو  )MDR-TB(
 لماعم ،%95  ةقثلا لماعم ،1.4  :لماتحلاا ةبسن ،لماتحلاا ةبسن(
 ،1.1 :لماتحلاا ةبسن ،لماتحلاا ةبسن( سنلجا وأ )3.0-0.7 :ةقثلا
 يماع  ينب  مايفو  .)1.4-0.8  :ةقثلا  لماعم  ،%95  ةقثلا  لماعم
 ةددعتلما  ةيودلأل  مواقلما  لسلا  تلادعم  تداز  ،2010و  1994
 ايروك  ةيروهجمو  اناوستوب  في  ناكسلا  ةماع  في  )MDR-TB(
.ةيكيرملأا ةدحتلما تايلاولاو ايفتلاو اينوتسإ في تضفخناو ويربو
 تلادعلما لىعأ قيثوت مت 2010و 2009 يماع ينب مايف جاتنتسلاا
 مت  يتلا  )MDR-TB(  ةددعتلما  ةيودلأل  مواقلما  لسلل  ةيلماعلا
 ةددعتلما ةيودلأل مواقلما لسلا في تاهاتجلاا لازت لاو .اهنع غلابلإا
 دوجو  مزليو  .تائيبلا  مظعم  في  ةحضاو  يرغ  )MDR-TB(
 .دنلهاو ايقيرفأ نم ةصاخ ،لضفأ حوسم تانايب وأ ةبقارم
摘要
抗结核病药物抗药性全球监察：分析更新，2007–2010











10% 的 MDR-TB 病例是广泛抗药性结核病。1994 年至 
2010 年期间全球所有初诊 TB 病例中有 3.4%（95% 置信
区间，CI：1.9–5.0）的病例观察到耐多药结核病，在复
诊 TB 病例中有 19.8%（95% CI：14.4–25.1）的病例观
察到耐多药结核病。未发现 MDR-TB 与 HIV 感染（优势
比，OR：1.4；95% CI：0.7–3.0）或性行为（OR：1.1
；95% CI：0.8–1.4）之间的整体性关联。在 1994 年至 
2010 年期间，博茨瓦纳、韩国和秘鲁一般大众的 MDR-
TB 率升高，而爱沙尼亚、拉脱维亚和美国的 MDR-TB 率
则降低。
结论 2009 年和 2010 年出现了有报告以来的全球最高 
MDR-TB 率。在多数环境中 MDR-TB 趋势依旧不明。需
要更好的监察或调查数据，尤其是非洲和印度的数据。
Résumé
Surveillance de la résistance aux médicaments antituberculeux dans le monde: une analyse actualisée, 2007-2010
Objectif Présenter une mise à jour globale de la tuberculose (TB) 
pharmacorésistante et explorer les tendances de 1994 à 2010.
Méthodes Les données relatives à la résistance aux médicaments des 
nouveaux patients de TB et de ceux traités antérieurement, telles que 
rapportées par les pays à l’Organisation mondiale de la Santé, ont été 
analysées. Ces données sont recueillies par des enquêtes représentatives 
auprès des patients ou des systèmes de surveillance basés sur des tests 
systématiques de sensibilité. Les associations entre la tuberculose ultra-
résistante (TB-UR), le virus de l’immunodéficience humaine (VIH) et le 
sexe ont été explorées par régression logistique.
Résultats En 2007-2010, 80 pays et 8 territoires ont fourni des données 
de surveillance. Parmi les cas nouveaux et traités antérieurement, la TB-UR 
était la plus élevée dans la Fédération de Russie (oblast de Mourmansk, 
28,9%) et la République de Moldavie (65,1%), respectivement. Dans 
trois pays de l’ex-Union soviétique et en Afrique du Sud, plus de 10% 
des cas de TB-UR étaient ultra-résistants. Globalement, en 1994-2010, la 
multirésistance aux médicaments a été observée chez 3,4% (intervalle 
de confiance 95%, IC: 1,9 à 5,0) de tous les nouveaux cas de TB et 19,8% 
(IC 95%: 14,4 à 25,1) des cas de TB traités antérieurement. Aucune 
association générale entre la TB-UR et l’infection au VIH (rapports de 
cotes, OR: 1,4, IC 95%: 0,7 à 3,0) ou le sexe (OR: 1,1, IC 95%: 0,8 à 1,4) n’a 
été trouvée. Entre 1994 et 2010, les taux de TB-UR dans la population 
générale ont augmenté au Botswana, en République de Corée et au 
Pérou et diminué en Estonie, Lettonie et aux Etats-Unis d’Amérique.
Conclusion Les taux mondiaux les plus élevés jamais signalés de TB-
UR ont été documentés en 2009 et 2010. Les tendances de la TB-UR 
sont encore peu claires dans la plupart des paramètres. De meilleures 
données de surveillance ou d’enquête sont nécessaires, surtout en 
provenance d’Afrique et d’Inde.
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Резюме 
Обзор устойчивости к воздействию противотуберкулезных препаратов в мире: новейший анализ, 
2007–2010 гг.
Цель Представить новейший глобальный анализ лекарственно-
устойчивого туберкулеза (TB) и исследовать тенденции в период 
с 1994 по 2010 гг.
Методы Были проанализированы данные об устойчивости к 
лекарственным препаратам среди новых и уже проходивших 
лечение от туберкулеза пациентов, полученные на основе 
докладов стран, направленных во Всемирную Организацию 
Здравоохранения. Эти данные были собраны посредством 
репрезентативных обследований пациентов или же 
с использованием систем мониторинга, основанных на 
обычном тестировании лекарственной устойчивости. 
Посредством логистической регрессии были исследованы 
связи между полирезистентным туберкулезом (MDR-TB), вирусом 
иммунодефицита человека (HIV) и полом.
Результаты В 2007–2010 гг. 80 стран и 8 территорий предоставили 
данные, полученные на основе проведенного мониторинга. 
Количество случаев полирезистентного туберкулеза среди 
новых или уже проходивших лечение от туберкулеза пациентов 
было самым высоким в Российской Федерации (Мурманская 
область, 28,9%) и Республике Молдова (65,1%), соответственно. 
В трех бывших республиках Советского Союза и Южной 
Африке более 10% случаев полирезистентного туберкулеза в 
основном являлись устойчивыми к воздействию медицинских 
препаратов. В мире, в период с 1994 по 2010 гг., лекарственная 
устойчивость наблюдалась в 3,4% (95% доверительный интервал, 
ДИ: 1,9–5,0) всех новых случаев заболевания туберкулезом 
и у 19,8% (95% доверительный интервал, ДИ: 14.4–25.1) 
пациентов, уже проходивших лечение от туберкулеза. Не было 
обнаружено каких-либо общих связей между полирезистентным 
туберкулезом, вирусом иммунодефицита человека (отношение 
рисков, ОР: 1,4; 95% ДИ: 0,7–3,0) или полом (ОР: 1,1; 95% ДИ: 
0,8–1,4). В период с 1994 по 2010 гг. темпы заболеваемости 
полирезистентным туберкулезом среди населения в целом 
увеличились в Ботсване, Республике Корея и Перу и снизились 
в Эстонии, Латвии и Соединенных Штатах Америки
Вывод Самый высокий глобальный уровень заболеваемости 
п о л и р е з и с те н т н ы м  т у б е р к у л е з о м  и з  к о гд а - л и б о 
зарегистрированных был отмечен в 2009 и 2010 гг. По большинству 
параметров тенденции в отношении полирезистентного 
туберкулеза остаются неясными. Необходимо улучшить систему 
мониторинга и сбора данных, в особенности в Африке и Индии.
Resumen
Vigilancia de la resistencia a los medicamentos contra la tuberculosis en todo el mundo: análisis actualizado, 2007–2010
Objetivo Presentar una actualización global de la situación de la 
tuberculosis (TB) resistente a los medicamentos y analizar las tendencias 
entre 1994 y 2010.
Método Se analizaron los datos sobre la resistencia a los medicamentos 
entre los pacientes recién diagnosticados con TB y los que habían 
recibido tratamiento con anterioridad, en base a los informes que los 
países remitieron a la Organización Mundial de la Salud. Dichos datos se 
recopilaron a través de encuestas representativas a pacientes o mediante 
sistemas de vigilancia basados en pruebas rutinarias de sensibilidad a 
los medicamentos. A través de una regresión logística se analizaron las 
asociaciones existentes entre la tuberculosis multirresistente (TB-MDR), 
el virus de la inmunodeficiencia humana y el sexo.
Resultados Entre 2007 y 2010, 80 países y 8 territorios facilitaron sus 
datos de vigilancia. Los niveles más elevados de TB-MDR entre los 
casos recién diagnosticados y previamente tratados se registraron en 
la Federación de Rusia (Murmansk oblast, 28,9%) y la República de 
Moldova (65,1%), respectivamente. En tres de los países de la antigua 
Unión Soviética y en Sudáfrica, más de un 10% de los casos de TB-MDR 
fueron extremadamente resistentes. Entre 1994 y 2010 se observó en 
todo el mundo una multirresistencia de un 3,4% (95% de intervalo de 
confianza, IC: 1,9–5,0) en todos los casos nuevos de TB y de un 19,8% 
(95% IC: 14,4–25,1) en los casos de TB previamente tratados. No se 
observaron asociaciones globales entre la TB-MDR y la infección por 
el VIH (cociente de posibilidades, OR: 1,4; IC del 95%: 0,7–3,0) ni con 
el sexo (OR: 1,1; IC del 95%: 0,8–1,4). Entre los años 1994 y 2010, las 
tasas de TB-MDR en la población general aumentaron en Botswana, la 
República de Corea y Perú y descendieron en Estonia, Letonia y Estados 
Unidos de América.
Conclusión En 2009 y 2010 se registraron las tasas globales de MDR-TB 
más altas de la historia. Las tendencias de TB-MDR siguen sin quedar 
claras en la mayoría de los entornos. Es necesaria una mejor vigilancia 
o más datos procedentes de encuestas, especialmente en los casos de 
África e India.
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Table 1. Countries and territories reporting dataa on multidrug resistant tuberculosis (MDR-TB), 2007–2010
Country or setting Source Year New cases Previously treated cases
Cases with 
DST results 












H R H R
Albania Surveillance 2010 186 0.5 3.2 0.5 19 5.3 31.6 –
Andorra Surveillance 2010 4 0.0 25.0 0.0 0 – – –
Australia Surveillance 2010 868 2.4 8.9 2.6 48 22.9 29.2 –
Austria Surveillance 2010 240 2.1 8.8 2.1 16 18.8 18.8 –
Bahamas Surveillance 2010 21 0.0 0.0 23.8 2 0.0 0.0 –
Bahrain Surveillance 2010 162 0.0 0.0 0.0 0 – – –
Bangladesh (14 districts 
covering 30 million 
population)
Surveillance 2008 – – – – 599 28.0 37.6 –
Belarus Surveillance 2010 1972 25.7 33.2 27.2 1697 60.2 66.7 –
Belgium Surveillance 2009 621 0.6 3.9 0.8 56 5.4 10.7 –
Benin Survey 2010 403 0.5 7.9 1.2 45 13.3 31.1 –
Bermuda Surveillance 2010 1 0.0 0.0 0.0 0 – – –
Bolivia (Plurinational 
State of )
Surveillance 2010 – – – – 664 16.0 24.4 16.6
Bosnia and Herzegovina Surveillance 2009 854 0.0 0.6 0.0 66 3.0 12.1 3.0
Botswana Survey 2008 924 2.5 7.6 3.6 137 6.6 10.3 13.2
Brunei Darussalam Surveillance 2010 181 0.0 2.8 0.0 5 0.0 0.0 0.0
Bulgaria Surveillance 2010 801 2.0 6.6 2.9 165 24.2 35.1 28.4
Cambodia Survey 2007 781 1.4 7.2 1.8 56 10.7 17.8 10.7
Canada Surveillance 2010 987 1.5 8.2 1.5 51 0.0 9.8 0.0
Central African Republic, 
Bangui and Bimbo
Survey 2009 225 0.4 9.3 0.4 – – – –
Chile Surveillance 2010 – – – – 276 2.9 13.4 7.2
China Survey 2007 3037 5.7 15.9 6.6 892 25.6 38.8 29.7
China, Hong Kong 
Special Administrative 
Region
Surveillance 2009 2056 0.7 4.6 1.0 234 2.6 7.7 2.6
China, Macao Special 
Administrative Region
Surveillance 2010 221 1.8 6.3 2.2 39 5.1 10.2 5.1
Colombia Surveillance 2010 – – – – 495 15.8 25.5 17.0
Curaçao Surveillance 2010 5 0.0 40.0 0.0 0 – – –
Cyprus Surveillance 2009 27 14.8 22.2 14.8 4 0.0 – –
Czech Republic Surveillance 2009 413 1.2 2.9 1.9 39 7.7 10.3 7.7
Denmark Surveillance 2009 209 0.5 6.7 0.5 33 3.0 12.1 3.0
El Salvador Surveillance 2009 – – – – 85 1.2 5.9 1.2
Estonia Surveillance 2010 197 18.3 25.9 18.8 61 44.3 50.9 44.3
Fiji Surveillance 2009 – – – – 2 0.0 0.0 0.0
Finland Surveillance 2010 239 2.1 6.7 2.5 3 12.5 12.5 12.5
France Surveillance 2009 1304 1.0 2.7 1.1 106 13.2 17.0 14.2
French Polynesia Surveillance 2009 42 0.0 0.0 0.0 4 0.0 0.0 0.0
Georgia Surveillance 2010 1987 9.5 23.1 9.9 558 30.6 44.0 31.1
Germany Surveillance 2010 2138 1.3 7.1 1.6 130 6.2 15.4 7.7
Greece Surveillance 2009 140 6.4 11.4 6.4 14 28.6 50.0 35.7
Guam Surveillance 2010 56 3.6 10.7 3.6 2 0.0 0.0 0.0
Hungary Surveillance 2009 486 3.3 8.4 3.7 55 7.3 18.2 7.3
Iceland Surveillance 2010 19 0.0 31.6 0.0 0 – – –
Indonesia, Central Java 
province
Survey 2006 1126 1.8 11.4 2.1 70 17.1 24.2 21.7
Ireland Surveillance 2010 176 1.1 5.1 2.2 21 0.0 4.8 0.0
Israel Surveillance 2010 245 4.9 11.4 7.3 2 0.0 50.0 0.0
Italy Surveillance 2009 1051 3.2 8.4 3.8 264 12.5 21.2 13.7
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Country or setting Source Year New cases Previously treated cases
Cases with 
DST results 












H R H R
Jordan Surveillance 2009 95 6.3 9.5 6.3 7 28.6 28.6 28.6
Kazakhstan Surveillance 2010 – – – – 4655 45.1 58.8 48.3
Kuwait Surveillance 2010 437 1.1 10.0 1.3 0 – – –
Latvia Surveillance 2010 613 10.3 25.8 10.3 102 23.5 39.2 23.5
Lebanon Surveillance 2010 – – – – 14 35.7 35.7 35.7
Lithuania Surveillance 2009 1074 10.6 21.4 11.1 404 51.5 61.6 52.2
Luxembourg Surveillance 2009 27 0.0 11.1 0.0 – – – –
Madagascar Survey 2007 810 0.5 4.6 0.5 51 3.9 9.8 5.9
Malta Surveillance 2009 17 0.0 5.9 0.0 0 – – –
Marshall Islands Surveillance 2010 68 1.5 3.0 1.5 3 0.0 0.0 0.0
Mauritius Surveillance 2010 105 1.0 2.9 1.0 7 14.3 14.3 14.3
Mexico Survey 2009 1584 2.4 8.5 2.6 191 6.5 15.5 10.9
Mongolia Surveillance 2010 – – – – 561 30.1 36.5 30.8
Mongolia Survey 2007 650 1.4 12.6 2.2 – – – –
Montenegro Surveillance 2010 61 0.0 4.9 0.0 12 0.0 0.0 0.0
Mozambique Survey 2007 1102 3.5 7.8 3.7 25 11.2 15.2 19.6
Myanmar Survey 2008 1071 4.2 5.2 4.9 299 10.0 11.7 10.7
Namibia Survey 2008 1054 3.8 13.5 4.6 354 16.4 38.4 22.0
Netherlands Surveillance 2010 741 1.3 8.5 1.4 29 3.4 13.7 3.4
New Zealand Surveillance 2009 237 2.5 9.3 2.5 8 12.5 12.5 12.5
Northern Mariana 
Islands
Surveillance 2010 17 0.0 5.9 0.0 0 – – –
Norway Surveillance 2009 210 3.8 9.0 4.3 20 0.0 10.0 0.0
Oman Surveillance 2010 185 0.0 8.1 0.5 8 12.5 12.5 12.5
Palau Surveillance 2010 11 0.0 0.0 0.0 0 – – –
Paraguay Survey 2008 319 0.3 1.9 0.9 48 14.6 16.7 14.6
Poland Surveillance 2008 3758 0.5 3.1 0.5 607 5.6 9.7 5.9
Portugal Surveillance 2009 1391 0.9 6.8 1.0 148 6.1 8.8 6.1
Puerto Rico Surveillance 2010 69 0.0 10.1 0.0 4 0.0 0.0 0.0
Qatar Surveillance 2010 324 1.2 5.8 1.2 0 – – –
Republic of Moldova Surveillance 2010 – – – – 1077 65.1 74.0 66.4
Russian Federation, 
Arkhangelsk oblast
Surveillance 2009b 292 25.7 – – 68 58.8 – –
Russian Federation, 
Belgorod oblast
Surveillance 2009b 358 19.8 – – 91 51.6 – –
Russian Federation, 
Bryansk oblast
Surveillance 2009b 560 11.1 – – 54 27.8 – –
Russian Federation, 
Ivanovo oblast
Surveillance 2009b 276 20.3 – – 52 57.7 – –
Russian Federation, 
Kaliningrad oblast
Surveillance 2009b 354 22.3 – – 51 43.1 – –
Russian Federation, 
Mary El Republic
Surveillance 2009b 366 15.6 – – 53 37.7 – –
Russian Federation, 
Murmansk oblast
Surveillance 2009b 190 28.9 – – 14 35.7 – –
Russian Federation, Orel 
oblast
Surveillance 2009b 256 6.3 – – 29 48.3 – –
Russian Federation, 
Pskov oblast
Surveillance 2009b 304 24.3 – – 44 50.0 – –
Russian Federation, 
Republic of Chuvashia
Surveillance 2009b 579 15.2 – – 92 45.7 – –
Russian Federation, 
Tomsk oblast
Surveillance 2009b 435 11.3 – – 80 53.8 – –
Russian Federation, 
Vladimir oblast
Surveillance 2009b 422 20.9 – – 55 32.7 – –
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Rwanda Surveillance 2010 – – – – 431 19.0 20.2 21.3
Serbia Surveillance 2008 923 0.7 2.0 0.7 130 7.7 12.3 7.7
Singapore Surveillance 2010 923 0.2 2.3 0.3 79 1.3 6.4 2.6
Slovakia Surveillance 2010 185 0.0 2.7 0.0 32 3.1 9.4 3.1
Slovenia Surveillance 2009 167 0.5 2.4 0.6 8 0.0 0.0 0.0
Sri Lanka Surveillance 2010 – – – – 378 1.6 5.3 2.6
Swaziland Survey 2009 352 7.7 13.4 8.0 231 33.9 45.3 36.4
Sweden Surveillance 2010 440 2.5 9.1 3.0 30 23.3 40.0 23.3
Switzerland Surveillance 2010 270 0.4 2 0.4 33 9.1 33.3 12.1
Tajikistan, Dushanbe city 
and Rudaki district
Survey 2009 139 16.5 26.6 16.6 125 61.6 74.4 64.8
Former Yugoslav 
Republic of Macedonia
Surveillance 2010 153 1.3 3.9 1.3 28 17.9 17.9 17.9
Uganda, Kampala Survey 2008 473 1.1 5.8 1.5 60 11.7 20.0 13.4
United Kingdom of 
Great Britain and 
Northern Ireland
Surveillance 2009 3957 0.9 6.6 1.1 364 3.3 7.7 4.1
United States of America Surveillance 2010 6514 1.1 7.5 1.5 293 4.4 16.0 5.8
DST, drug susceptibility testing; H, isoniazid; R, rifampicin.
a Data from the most recent year are shown.
b 2009 data for new TB cases and 2008 data for previously treated TB cases.
Note: The data were obtained from the World Health Organization.10,11
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Table 2. Countries and territories reporting dataa on extensively drug-resistant tuberculosis (XDR-TB), 2007–2010
Country or territory Source Year No. of cases of 
MDR-TB
MDR-TB cases with DST  
results for 2nd-line drugs
No. of cases of XDR-TB 
(%)
Albania Surveillance 2010 2 2 0 (0.0)
Australia Surveillance 2010 32 32 1 (3.1)
Austria Surveillance 2010 15 15 1 (6.7)
Bangladesh (14 districts 
covering 30 million 
population)b
Surveillance 2008 168 168 1 (0.6)
Belgium Surveillance 2009 10 10 3 (30.0)
Botswana Survey 2008 32 24 0 (0.0)
Bulgaria Surveillance 2008 32 28 0 (0.0)
Canada Surveillance 2010 15 14 1 (7.1)
China Survey 2008 401 401 29 (7.2)
China, Hong Kong Special 
Administrative Region
Surveillance 2009 3 3 0 (0.0)
China, Macao Special 
Administrative Region
Surveillance 2010 6 6 0 (0.0)
Cyprus Surveillance 2008 1 1 0 (0.0)
Czech Republic Surveillance 2008 11 10 1 (10.0)
Denmark Surveillance 2007 2 2 0 (0.0)
Estonia Surveillance 2010 63 61 12 (19.7)
Georgia Surveillance 2010 359 313 30 (9.6)
Greece Surveillance 2009 14 9 3 (33.3)
Guam Surveillance 2010 2 2 0 (0.0)
Iceland Surveillance 2008 1 1 0 (0.0)
India, Gujarat state Survey 2006 216 216 7 (3.2)
Israel Surveillance 2010 12 12 1 (8.3)
Italy Surveillance 2009 82 32 1 (3.1)
Latvia Surveillance 2010 87 86 13 (15.1)
Marshall Islands Surveillance 2010 1 1 0 (0.0)
Montenegro Surveillance 2009 1 1 0 (0.0)
Namibia Survey 2008 100 100 0 (0.0)
Norway Surveillance 2008 4 4 0 (0.0)
Oman Surveillance 2010 1 1 0 (0.0)
Paraguay Survey 2008 8 8 0 (0.0)
Poland Surveillance 2008 52 52 5 (9.6)
Qatar Surveillance 2010 4 4 0 (0.0)
Singapore Surveillance 2010 3 3 0 (0.0)
Slovakia Surveillance 2010 1 1 0 (0.0)
South Africa Surveillance 2008 8026 5451 572 (10.5)
Swaziland Survey 2009 122 122 1 (0.8)
Sweden Surveillance 2009 13 9 0 (0.0)
Switzerland Surveillance 2010 8 8 0 (0.0)
Tajikistan, Dushanbe city and 
Rudaki district
Survey 2009 100 100 21 (21.0)
Former Yugoslav Republic of 
Macedonia
Surveillance 2010 7 5 1 (20.0)
United Kingdom of Great 
Britain and Northern Ireland
Surveillance 2009 58 40 2 (5.0)
United States of America Surveillance 2010 92 59 1 (1.7)
DST, drug susceptibility testing; MDR-TB, multidrug resistant tuberculosis.
a Data from the most recent year are shown.
b Only previously treated cases.
Note: The data were obtained from the World Health Organization.10,11
